Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

About six months ago, I wrote an article on Voyager Therapeutics, Inc. (NASDAQ: VYGR ) highlighting the pipeline advances and stable financial position, supporting a “Strong Buy” rating. Given that VYGR’s shares have fallen by 35% sinceOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising m ...